184 related articles for article (PubMed ID: 34551064)
1. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.
Menghrajani K; Gomez-Arteaga A; Madero-Marroquin R; Zhang MJ; Bo-Subait K; Sanchez J; Wang HL; Aljurf M; Assal A; Bacher VU; Badawy SM; Bejanyan N; Bhatt VR; Bredeson C; Byrne M; Castillo P; Cerny J; Chhabra S; Ciurea SO; DeFilipp Z; Farhadfar N; Gadalla S; Gale RP; Ganguly S; Gowda L; Grunwald MR; Hashmi S; Hildebrandt G; Kanakry CG; Kansagra A; Khimani F; Krem M; Lazarus H; Liu H; Martino R; Michelis FV; Nathan S; Nishihori T; Olsson R; Reshef R; Rizzieri D; Rowe JM; Savani BN; Seo S; Sharma A; Solh M; Ustun C; Verdonck LF; Hourigan C; Sandmaier B; Litzow M; Kebriaei P; Weisdorf D; Zhang Y; Tallman MS; Saber W
Blood Adv; 2022 Jan; 6(3):828-847. PubMed ID: 34551064
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan.
Miyamura T; Kudo K; Tabuchi K; Ishida H; Tomizawa D; Adachi S; Goto H; Yoshida N; Inoue M; Koh K; Sasahara Y; Fujita N; Kakuda H; Noguchi M; Hiwatari M; Hashii Y; Kato K; Atsuta Y; Okamoto Y
Leuk Res; 2019 Dec; 87():106263. PubMed ID: 31707119
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
Michelis FV; Gupta V; Zhang MJ; Wang HL; Aljurf M; Bacher U; Beitinjaneh A; Chen YB; DeFilipp Z; Gale RP; Kebriaei P; Kharfan-Dabaja M; Lazarus HM; Nishihori T; Olsson RF; Oran B; Rashidi A; Rizzieri DA; Tallman MS; de Lima M; Khoury HJ; Sandmaier BM; Weisdorf D; Saber W;
Cancer; 2017 Jun; 123(11):2035-2042. PubMed ID: 28117898
[TBL] [Abstract][Full Text] [Related]
4. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial.
Schetelig J; Schaich M; Schäfer-Eckart K; Hänel M; Aulitzky WE; Einsele H; Schmitz N; Rösler W; Stelljes M; Baldus CD; Ho AD; Neubauer A; Serve H; Mayer J; Berdel WE; Mohr B; Oelschlägel U; Parmentier S; Röllig C; Kramer M; Platzbecker U; Illmer T; Thiede C; Bornhäuser M; Ehninger G;
Leukemia; 2015 May; 29(5):1060-8. PubMed ID: 25434303
[TBL] [Abstract][Full Text] [Related]
6. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
7. Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/KMT2A rearrangements.
Yuen KY; Liu Y; Zhou YZ; Wang Y; Zhou DH; Fang JP; Xu LH
Cancer Med; 2023 Jan; 12(2):1418-1430. PubMed ID: 35833755
[TBL] [Abstract][Full Text] [Related]
8. Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission.
Konuma T; Kanda J; Yamasaki S; Harada K; Shimomura Y; Terakura S; Mizuno S; Uchida N; Tanaka M; Doki N; Ozawa Y; Nakamae H; Sawa M; Matsuoka KI; Morishige S; Maruyama Y; Ikegame K; Kimura T; Kanda Y; Ichinohe T; Atsuta Y; Yanada M
Transplant Cell Ther; 2021 Apr; 27(4):334.e1-334.e11. PubMed ID: 33836881
[TBL] [Abstract][Full Text] [Related]
9. Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, et al. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022;6(3):828-847.
Blood Adv; 2023 Feb; 7(3):395. PubMed ID: 36716115
[No Abstract] [Full Text] [Related]
10. Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS.
Gupta V; Kim S; Hu ZH; Liu Y; Aljurf M; Bacher U; Beitinjaneh A; Cahn JY; Cerny J; Copelan E; Gadalla SM; Gale RP; Ganguly S; George B; Gerds AT; Gergis U; Hamilton BK; Hashmi S; Hildebrandt GC; Kamble RT; Kindwall-Keller T; Lazarus HM; Liesveld JL; Litzow M; Maziarz RT; Nishihori T; Olsson RF; Rizzieri D; Savani BN; Seo S; Solh M; Szer J; Verdonck LF; Wirk B; Woolfrey A; Yared JA; Alyea EP; Popat UR; Sobecks RM; Scott BL; Nakamura R; Saber W
Blood Adv; 2020 Oct; 4(19):4748-4757. PubMed ID: 33007075
[TBL] [Abstract][Full Text] [Related]
11. The adverse impact of ecotropic viral integration site-1 (EVI1) overexpression on the prognosis of acute myeloid leukemia with KMT2A gene rearrangement in different risk stratification subtypes.
Liu XX; Pan XA; Gao MG; Kong J; Jiang H; Chang YJ; Zhang XH; Wang Y; Liu KY; Chen Z; Zhao XS; Huang XJ
Int J Lab Hematol; 2023 Apr; 45(2):195-203. PubMed ID: 36358022
[TBL] [Abstract][Full Text] [Related]
12. Pediatric acute myeloid leukemia patients with
Yang W; Qin M; Jia C; Yang J; Chen W; Luo Y; Jing Y; Wang B
Hematology; 2022 Dec; 27(1):583-589. PubMed ID: 35617149
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation.
Liu J; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Cheng YF; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
Ann Hematol; 2021 May; 100(5):1267-1281. PubMed ID: 33712867
[TBL] [Abstract][Full Text] [Related]
14. Impact of Cytogenetic Risk on Outcomes of Non-T-Cell-Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Nagler A; Labopin M; Dholaria B; Ciceri F; Fraccaroli A; Blaise D; Fanin R; Bruno B; Forcade E; Vydra J; Chevallier P; Bulabois CE; Jindra P; Bornhäuser M; Canaani J; Sanz J; Savani BN; Spyridonidis A; Giebel S; Brissot E; Bazarbachi A; Esteve J; Mohty M
Transplant Cell Ther; 2022 Nov; 28(11):773.e1-773.e8. PubMed ID: 36031079
[TBL] [Abstract][Full Text] [Related]
15. KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia.
Kanayama T; Imamura T; Kawabe Y; Osone S; Tahara J; Iwasaki F; Miyagawa N; Goto H; Imashuku S; Hosoi H
Int J Hematol; 2018 Dec; 108(6):665-669. PubMed ID: 30143999
[TBL] [Abstract][Full Text] [Related]
16. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
[TBL] [Abstract][Full Text] [Related]
17. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
[TBL] [Abstract][Full Text] [Related]
18. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Chen EC; Li S; Eisfeld AK; Luskin MR; Mims A; Jones D; Antin JH; Cutler CS; Koreth J; Ho VT; Gooptu M; Romee R; El-Jawahri A; McAfee SL; DeFilipp Z; Soiffer RJ; Chen YB; Fathi AT
Transplant Cell Ther; 2021 Jun; 27(6):479.e1-479.e7. PubMed ID: 33840625
[TBL] [Abstract][Full Text] [Related]
19. Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics.
Yamasaki S; Yoshimoto G; Ogawa R; Aoki K; Higuchi M; Harada N; Arima F; Kondo S; Matubara F; Takahashi T; Uike N; Miyamoto T; Okamura S; Akashi K;
Ann Hematol; 2015 Jul; 94(7):1159-65. PubMed ID: 25704584
[TBL] [Abstract][Full Text] [Related]
20. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
